(Press-News.org) HOUSTON - An oral medication produces significant and lasting relief for patients with myelofibrosis, a debilitating and lethal bone marrow disorder, researchers at The University of Texas MD Anderson Cancer Center report in the Sept. 16 New England Journal of Medicine.
Myelofibrosis is caused by the accumulation of malignant bone marrow cells that trigger an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, causing anemia.
"The problem with myelofibrosis is the lack of available therapies for patients - there are none approved for this disease today," said principal investigator Srdan Verstovsek, M.D., Ph.D., associate professor in M. D. Anderson's Department of Leukemia. Average life expectancy for people with this disease is 5 to 7 years. Available therapies approved for other diseases provide little response and are mainly palliative.
"This experimental drug is the first to target one of the underlying abnormalities in the malignant cells that cause myelofibrosis," Verstovsek said. "It provides unprecedented reduction of enlarged spleens that are a central characteristic of the disease, and relieves pain, fatigue and other symptoms, improving quality of life."
Swollen spleens cause pain, malnutrition
"Interestingly, other organs, mainly the spleen, attempt to take over the production of blood cells. Bone marrow forms in the spleen," Verstovsek said. Malignant cells also accumulate there. "The growing spleen causes significant problems for the patient, and not just because it's painful. It compresses the stomach and bowels, so patients suffer malnutrition and lose weight. The ability to walk and to bend is affected, and the body deteriorates overall."
End-stage patients resemble the severely malnourished, with bloated abdomens and thin limbs. Patients on the study gained weight while on the medication.
The phase I/II clinical trial of INCB018424, a JAK1 and JAK2 inhibitor developed by Incyte Corp., established maximum tolerated doses and then optimal dosing regimens for the drug, which targets abnormal signaling caused by a specific mutation in the JAK2 gene that was discovered in 2005 in patients with myelofibrosis.
The clinical trial began in June 2007 at MD Anderson and the Mayo Clinic and enrolled 153 patients, all of whom had either advanced disease or were newly diagnosed with high intermediate- or high-risk myelofibrosis. Clinical responses have been maintained and 115 patients (75 percent) remain on the trial.
Most patients benefited, with those on optimal doses experiencing:
A median reduction in spleen volume, as measured by magnetic resonance imaging, of 33 percent at six months, with 48 percent enjoying reductions of 35 percent or higher. This equals a median reduction of 52 percent in the length of the spleen below the ribcage, measured by palpation, which is how spleen size is typically measured in clinical practice.
Swift and lasting spleen reduction; 70 percent to 82 percent of patients on the three optimal dosing regimens had spleen reduction of at least 25 percent that occurred within the first two months of therapy and lasted beyond a year.
Rapid and lasting improvement in symptom score, with 51 percent of patients achieving a 50 percent reduction at one month, and 58 percent maintaining that reduction at six months.
Greater exercise capacity as measured in a six-minute walk. Patients increased their distance by a median of 34 meters at one month and 71 meters at six months.
Median weight gain ranging from 14.5 pounds to 20.6 lbs after one year.
Symptom improvement coincided with a quick and sustained reduction in a variety of inflammatory cytokines involved in disease biology.
The main side effect is lowered blood cell counts in some patients, which can be remedied by lower doses or temporarily halting therapy.
"The JAK2V617F mutation is one of several involved in myelofibrosis. It's the most prevalent, found in about half of patients. But it's not the sole cause of the disease," Verstovsek noted. "Myelofibrosis is too complex to be eliminated by a single drug. It will probably take combination therapies to cure it."
Normally, JAK2 is turned on by various growth factors to make new blood cells as needed. The JAK2V617F mutation leaves the JAK2 enzyme permanently turned on, which causes the overgrowth of bone marrow cells at the heart of myelofibrosis.
While the JAK2 inhibitor was expected to help patients with JAK2 mutations, the drug worked whether they had the mutation or not. "This suggests that patients who do not have specific mutations still have a very active JAK signaling pathway and can benefit from JAK inhibition," Verstovsek said. "However, because the drug also inhibits normal JAK2, it can lead to low blood counts that can limit dosing."
INFORMATION:
Pivotal Phase III studies for INCB018424 in myelofibrosis are under way in the United States, Canada, Australia and Europe (www.comfortstudy.com)
About 3,000 new cases of myelofibrosis occur annually in the United States. The Phase I/II trial was the largest ever conducted for the disease.
The clinical trial was funded by Incyte Corporation. Verstovsek has received research funding from Incyte.
Co-authors with Verstovsek are Hagop Kantarjian, M.D., Deborah Thomas, M.D., Zeev Estrov, M.D., and Jorge Cortes, M.D., of the MD Anderson Department of Leukemia; Ruben Mesa, M.D., of Mayo Clinic in Scottsdale, Ariz.; Animesh D. Pardanani, M.B.B.S., Ph.D., and Ayalew Tefferi, M.D., of Mayo Clinic Department of Hematology in Rochester, Minn; and Edward C Bradley, M.D., Susan Erickson-Viitanen, Ph.D., Kris Vaddi, Ph.D., and Richard Levy, M.D., of Incyte Corporation.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For seven of the past nine years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Tackling today's complex scientific questions often requires work from interdisciplinary collaborative research teams – and working in those teams can create its own problems. Now a group of researchers from around the country, including North Carolina State University, has published a commentary in the journal Science Translational Medicine outlining a new field of study that will help resolve problems facing interdisciplinary research teams.
The new area of study, called the "science of team science," or SciTS (rhymes with sights), focuses on what works and what doesn't ...
Johns Hopkins scientists who specialize in unconventional hunts for genetic information outside nuclear DNA sequences have bagged a weighty quarry — 13 genes linked to human body mass. The experiments screened the so-called epigenome for key information that cells remember other than the DNA code itself and may have serious implications for preventing and treating obesity, the investigators say.
"Some of the genes we found are in regions of the genome previously suspected but not confirmed for a link to body mass index and obesity," says co-lead investigator Andrew Feinberg, ...
Your friends are probably more popular than you are. And this "friendship paradox" may help predict the spread of infectious disease.
Nicholas Christakis, professor of medicine, medical sociology and sociology at Harvard University, and James Fowler, professor of medical genetics and political science at the University of California, San Diego, used the paradox to study the 2009 flu epidemic among 744 students. The findings, the researchers say, point to a novel method for early detection of contagious outbreaks.
Analyzing a social network and monitoring the health ...
The traditional practice of using night dreams to make major life decisions is in widespread use among modern Muslims, reveals a new study whose author is speaking at the British Science Festival on Thursday September 16*.
Interviews with 60 Muslims in the UK, North America, Europe and Pakistan have revealed that night dreams are being used to make choices on issues like marriage, business, career development and politics.
Research leader, Durham University anthropologist Dr Iain Edgar focused on the centuries-old practice of Istikhara, or Islamic 'dream incubation'. ...
NEW YORK, N.Y. (September 15, 2010) – Autism Speaks, the world's largest autism science and advocacy organization, and an international consortium of researchers, along with participating families, joined together to announce additional new autism genetic discoveries. The results were published today in Science Translational Medicine.
Based on analysis of genomes collected from almost 2,250 individuals, including almost 2,000 with ASD and 246 with intellectual disabilities, and more than 10,000 controls, the researchers found PTCHD1 mutations or copy number variant (CNV) ...
The combination of depression and heart disease seems to be far more lethal than having either one of these conditions in isolation, suggests research published online in Heart.
Previous research has indicated that people who are depressed, but otherwise healthy, are more likely to develop coronary heart disease, irrespective of what other risk factors they might have.
And people who are depressed are more likely to die from all causes, but it still remains unclear as to whether depression is more fatal for those with heart disease than it is for those without.
The ...
Even the lowest possible dose of aspirin (75 mg) can ward off bowel cancer, if taken regularly, finds research published online in the journal Gut.
This protective effect is apparent after just one year and in the general population, not just those considered to be at risk of developing the disease, which is the second most common cause of cancer death in the world, killing almost half a million people every year.
Although previous research has shown that aspirin protects against bowel cancer, it is not known what the most effective dose is and how long it needs to ...
A study published in the international scientific journal Addiction reveals that restrictions on pub closing times imposed in 2008 within the Australian city of Newcastle have reduced the assault rate by 37 per cent.
The study, conducted at the University of Newcastle, shows the number of assaults in the Central Business District (CBD) fell from 33 per month before the restrictions were put in place, to 22 afterwards.
The team of researchers, led by Associate Professor Kypros Kypri, compared the Newcastle CBD assault rates with those in the nearby suburb of Hamilton, ...
Policymakers should increase their sense of urgency to stop the global spread of chronic diseases such as heart disease, cancer and diabetes that threaten the health and economies of industrialized and developing nations alike, Emory University global health researchers say.
Writing in the current issue of The New England Journal of Medicine, authors K. M. Venkat Narayan, MD, Mohammed Ali, MBChB, MSc, and Jeffrey Koplan, MD, MPH, assert that the worldwide spread of chronic conditions, also known as noncommunicable diseases, offers a unique opportunity for low-, middle- ...
Rosemont, Ill. – Several health plans have introduced physician rating systems to offer consumers more information when choosing their doctors. However, a recent study presented in the September issue of the Journal of Bone and Joint Surgery (JBJS) reveals that physician-tiering guidelines and results are not consistent across insurance companies, do not fully define quality; and could confuse consumers.
Since affordable and more accessible health care is a critical national challenge, the use of rating systems will increase as one response to rising costs. Doctors ...
